If youâre wanting to add some ASX 200 shares to your portfolio, then you may want to check out the two listed below.
Hereâs why these ASX 200 shares come highly rated:
Goodman Group (ASX: GMG)
The first ASX 200 share to look at is Goodman Group. It is an integrated commercial and industrial property group which has generated consistently strong returns for investors over the last decade.
This has been underpinned by the diversity of Goodman’s portfolio and its exposure to quick growing markets such as ecommerce.
Pleasingly, the ecommerce market has resulted in strong demand from blue chip customers such as Amazon, Showpo, and Walmart. And given how the shift to online shopping is only really getting started, these properties look set to be in strong demand for a long time to come.
One broker that is very positive on Goodman is Goldman Sachs. It has a buy rating and $25.40 price target on its shares.
ResMed Inc. (ASX: RMD)
Another ASX 200 share that has been rated as a buy is ResMed. It is a medical device company aiming to change lives by developing, manufacturing, and distributing innovative medical devices and cloud-based software solutions. These solutions help to better diagnose, treat, and manage sleep-disordered breathing, chronic obstructive pulmonary disease (COPD), and other key chronic diseases.
Demand has been strong for its innovative products in recent years, leading to stellar sales and earnings growth.
The good news is that ResMed appears well-placed to continue this positive form in the future. This is thanks to its world-class products, the massive number of undiagnosed sleep apnoea sufferers globally, and its rapidly growing digital health ecosystem.
Credit Suisse is positive on the company and has an outperform rating and $40.00 price target on its shares.
The post Experts name 2 outstanding ASX 200 shares to buy right now appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now
See The 5 Stocks
*Returns as of September 1 2022
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Looking to buy ASX shares? Expert reveals ‘one metric to assess the quality of a business’
- I regret not buying 2 ASX shares that became 10-baggers: fundie
- One ‘safe’ and one ‘exciting’ ASX share to own for years like Warren Buffett: fund manager
- 2 blue chip ASX 200 shares to boost your portfolio: experts
- Analysts name 2 excellent blue chip ASX 200 shares to buy now
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/e7UYftu